Author(s):
Gitima Deka, Nagarathna Pkm, Moqbel Ali Moqbel Redhwan, Melvin Mariyam Varghese
Email(s):
mailgitima@gmail.com
DOI:
10.5958/0974-360X.2020.00712.X 
Address:
Gitima Deka, Nagarathna Pkm, Moqbel Ali Moqbel Redhwan, Melvin Mariyam Varghese
Department of Pharmacology, Karnataka College of Pharmacy, Bangalore-560064, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
Interferon gamma is a sort of cytokine which has functions in immune responses and tumour safe surveillance[1]. One essential mechanism of cross-guideline by restricting cytokines is hindrance of signal transduction, including restraint of Janus kinase-STAT motioning by silencers of cytokine signalling, however when motioning by the IFN? receptor initiates the Janus kinase (JAK)– signal transducer pathway to actuate the outflow of established interferon-invigorated qualities that have key safe effector functions[1,2]. There is acritical job of epigenetic instrument in adjusting and transmitting signals amid macrophage polarization and reinventing which is utilized for averting constant fiery disease[3]. Immunotherapy with PD-1 checkpoint barricade is viable in just a minority of patients with malignancy, the known insusceptible avoidance atoms PD-L1 and CD47, and affirmed that surrenders in interferon-? signalling made obstruction immunotherapy. Likewise, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells expanded the viability of immunotherapy by improving interferon-?-interceded consequences for antigen introduction and development suppression[4]. This Review focuses on ongoing advances for the comprehension of the transcriptional, chromatin-based the newfound impacts of IFN? on different leukocytes, fat tissue cells, neurons and tumour cells that have critical ramifications for autoimmunity, metabolic infections, and resistant checkpoint barricade malignant growth treatment.
Cite this article:
Gitima Deka, Nagarathna Pkm, Moqbel Ali Moqbel Redhwan, Melvin Mariyam Varghese. IFNγ: Signalling, Epigenetics and Roles in Immunity, Metabolism, Disease and Cancer Immunotherapy. Research J. Pharm. and Tech. 2020; 13(8):4028-4032. doi: 10.5958/0974-360X.2020.00712.X
Cite(Electronic):
Gitima Deka, Nagarathna Pkm, Moqbel Ali Moqbel Redhwan, Melvin Mariyam Varghese. IFNγ: Signalling, Epigenetics and Roles in Immunity, Metabolism, Disease and Cancer Immunotherapy. Research J. Pharm. and Tech. 2020; 13(8):4028-4032. doi: 10.5958/0974-360X.2020.00712.X Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-8-85
REFERENCES:
1. Ivashkiv L. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nature Reviews Immunology. 2018;18(9):545-558.
2. Herrero C, Hu X, Li W, Samuels S, Sharif M, Kotenko S et al. Reprogramming of IL-10 Activity and Signaling by IFN-γ. The Journal of Immunology. 2003;171(10):5034-5041.
3. vashkiv L. Epigenetic regulation of macrophage polarization and function. Trends in Immunology. 2013;34(5):216-223.
4. Manguso R, Pope H, Zimmer M, Brown F, Yates K, Miller B et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418.
5. Park S, Kang K, Giannopoulou E, Qiao Y, Kang K, Kim G et al. Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation. Nature Immunology. 2017;18(10):1104-1116.
6. 6. del Rio M, Buhler L, Gibbons C, Tian J, Rodriguez-Barbosa J. PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. Transplant International. 2008.
7. 7. Däbritz J, Menheniott T. Linking Immunity, Epigenetics, and Cancer in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2014;20(9):1638-1654.
8. Herrero C, Hu X, Li W, Samuels S, Sharif M, Kotenko S et al. Reprogramming of IL-10 Activity and Signaling by IFN-γ. The Journal of Immunology. 2003;171(10):5034-5041.
9. Su X, Yu Y, Zhong Y, Giannopoulou E, Hu X, Liu H et al. Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature Immunology. 2015;16(8):838-849.
10. Glass C, Natoli G. Molecular control of activation and priming in macrophages. Nature Immunology. 2015;17(1):26-33.
11. Cheon H, Yang J, Stark G. The Functions of Signal Transducers and Activators of Transcriptions 1 and 3 as Cytokine-Inducible Proteins. Journal of Interferon and Cytokine Research. 2011; 31(1): 33-40.
12. Wienerroither S, Shukla P, Farlik M, Majoros A, Stych B, Vogl C et al. Cooperative Transcriptional Activation of Antimicrobial Genes by STAT and NF-κB Pathways by Concerted Recruitment of the Mediator Complex. Cell Reports. 2015;12(2):300-312.
13. Foster S, Hargreaves D, Medzhitov R. Erratum: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature. 2008;451(7174):102-102.
14. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S et al. Latent Enhancers Activated by Stimulation in Differentiated Cells. Cell. 2013;152(1-2):157-171.
15. Smale S, Tarakhovsky A, Natoli G. Chromatin Contributions to the Regulation of Innate Immunity. Annual Review of Immunology. 2014;32(1):489-511.
16. Biswas S, Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends in Immunology. 2009;30(10):475-487.
17. O'Neill L, Kishton R, Rathmell J. A guide to immunometabolism for immunologists. Nature Reviews Immunology. 2016;16(9):553-565.
18. Hu X, Paik P, Chen J, Yarilina A, Kockeritz L, Lu T et al. IFN-γ Suppresses IL-10 Production and Synergizes with TLR2 by Regulating GSK3 and CREB/AP-1 Proteins. Immunity. 2006;24(5):563-574.
19. Su X, Yu Y, Zhong Y, Giannopoulou E, Hu X, Liu H et al. Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature Immunology. 2015;16(8):838-849.
20. Villarino A, Kanno Y, O'Shea J. Mechanisms and consequences of Jak–STAT signaling in the immune system. Nature Immunology. 2017;18(4):374-384.
21. Weizman O, Adams N, Schuster I, Krishna C, Pritykin Y, Lau C et al. ILC1 Confer Early Host Protection at Initial Sites of Viral Infection. Cell. 2017;171(4):795-808.
22. Panduro M, Benoist C, Mathis D. Treg cells limit IFN-γ production to control macrophage accrual and phenotype during skeletal muscle regeneration. Proceedings of the National Academy of Sciences. 2018;115(11):E2585-E2593.
23. Schmid J, Côte M, Ménager M, Burgess A, Nehme N, Ménasché G et al. Inherited defects in lymphocyte cytotoxic activity. Immunological Reviews. 2010;235(1):10-23.
24. Avau A, Mitera T, Put S, Put K, Brisse E, Filtjens J et al. Systemic Juvenile Idiopathic Arthritis-like Syndrome in Mice Following Stimulation of the Immune System With Freund's Complete Adjuvant: Regulation by Interferon-γ. Arthritis and Rheumatology. 2014;66(5):1340-1351.
25. Reinhardt R, Liang H, Bao K, Price A, Mohrs M, Kelly B et al. A Novel Model for IFN-γ–Mediated Autoinflammatory Syndromes. The Journal of Immunology. 2015;194(5):2358-2368.
26. Salter M, Stevens B. Microglia emerge as central players in brain disease. Nature Medicine. 2017;23(9):1018-1027.
27. Manguso R, Pope H, Zimmer M, Brown F, Yates K, Miller B et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418.
28. Shirey K, Carlin J. Chlamydiae Modulate Gamma Interferon, Interleukin-1 , and Tumor Necrosis Factor Alpha Receptor Expression in HeLa Cells. Infection and Immunity. 2006;74(4):2482-2486.
29. Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L et al. Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell. 2016;165(5):1092-1105.
30. Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature. 2017;545(7652):98-102.